Medicine and Dentistry
Abdominal Cancer
43%
Adenocarcinoma
31%
Adjuvant Therapy
10%
Anthracycline
10%
Biological Marker
11%
Biopsy Technique
12%
Chemoradiotherapy
100%
Cholangiocarcinoma
24%
Circulating Tumor Cell
23%
Circulating Tumor DNA
19%
Cisplatin
15%
Colorectal Carcinoma
10%
Colorectal Liver Metastasis
16%
Diseases
27%
Docetaxel
33%
Esophageal Adenocarcinoma
11%
Esophageal Cancer
69%
Esophageal Cancer
32%
Esophagectomy
22%
Esophagus
21%
Ex Vivo
11%
Floxuridine
12%
Fluorodeoxyglucose F 18
13%
Fluorouracil
24%
Folinic Acid
24%
Gastroesophageal Junction
25%
Hazard Ratio
10%
Hepatic Arterial Infusion
32%
Immunotherapy
20%
Intraperitoneal Chemotherapy
24%
Liver Metastasis
11%
Malignant Neoplasm
27%
Meta-Analysis
40%
Metastatic Carcinoma
29%
Metastatic Colorectal Cancer
16%
Neoadjuvant Therapy
14%
Neoplasm
39%
Next Generation Sequencing
9%
Overall Survival
85%
Oxaliplatin
28%
Paclitaxel
18%
Peritoneum Metastasis
32%
Primary Tumor
18%
Radiation Therapy
17%
Recurrent Disease
11%
Retrospective Cohort Study
11%
Symptomatic Treatment
10%
Systematic Review
40%
Systemic Therapy
16%
Targeted Therapy
12%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
25%
Adenocarcinoma
31%
Anthracycline
8%
Bile Duct Carcinoma
16%
Biological Marker
9%
Cabazitaxel
8%
Chemoradiation Therapy
62%
Chemotherapy
66%
Chemotherapy-Induced Peripheral Neuropathy
8%
Cimetidine
8%
Circulating Tumor DNA
11%
Cohort Study
19%
Colorectal Carcinoma
10%
Diseases
10%
Docetaxel
22%
Epidermal Growth Factor Receptor
8%
Esophageal Adenocarcinoma
9%
Esophageal Squamous Cell Carcinoma
9%
Esophagus Cancer
43%
Floxuridine
10%
Fluorodeoxyglucose F 18
9%
Fluorouracil
15%
Folinic Acid
15%
Head and Neck Squamous Cell Carcinoma
8%
Immunotherapy
16%
Infusion Pump
16%
Intraperitoneal Chemotherapy
16%
Liver Metastasis
8%
Malignant Neoplasm
36%
Metastatic Colorectal Cancer
17%
Metformin
8%
Neoplasm
48%
Observational Study
8%
Organic Cation Transporter 2
8%
Oropharynx Cancer
8%
Oropharynx Carcinoma
8%
Oropharynx Squamous Cell Carcinoma
8%
Overall Survival
54%
Oxaliplatin
20%
Paclitaxel
13%
Peritoneum Metastasis
24%
Pharmacokinetics
8%
Polyethylene Terephthalate
10%
Primary Tumor
14%
Prospective Cohort Study
8%
Prostate Cancer
8%
Stomach Adenocarcinoma
9%
Systemic Treatment
8%
Trastuzumab
8%
Trifluridine
8%